SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Brinker Scott M | President and CEO, Director | 2026-05-29 | Grant/award | 1347 | $21K |
| Brinker Scott M | President and CEO, Director | 2026-05-29 | Tax withholding | 114 | $2K |
| Johnston Shawn G | EVP and CAO | 2026-05-29 | Grant/award | 1358 | $21K |
| Johnston Shawn G | EVP and CAO | 2026-05-29 | Tax withholding | 76 | $1K |
| Mabry Adam G | CIO | 2026-05-29 | Grant/award | 625 | $10K |
| Mabry Adam G | CIO | 2026-05-29 | Tax withholding | 43 | $823 |
| Moses Kelvin O | Chief Financial Officer | 2026-05-29 | Grant/award | 937 | $14K |
| Moses Kelvin O | Chief Financial Officer | 2026-05-29 | Tax withholding | 65 | $1K |
| Patadia Ankit B. | EVP and Treasurer | 2026-05-29 | Grant/award | 1358 | $21K |
| Patadia Ankit B. | EVP and Treasurer | 2026-05-29 | Tax withholding | 94 | $2K |
| Thomas John T | Director | 2026-05-29 | Grant/award | 1385 | $21K |
| Thomas John T | Director | 2026-05-29 | Tax withholding | 78 | $1K |
| Bohn Scott R | CDO and Head of Lab | 2026-05-12 | Open-market sell | 10989 | $214K |
| Cartwright Brian G. | Director | 2026-05-06 | Grant/award | 9744 | $0 |
| Connor James B. | Director | 2026-05-06 | Grant/award | 9744 | $0 |
| Griffin R Kent Jr | Director | 2026-05-06 | Grant/award | 9744 | $0 |
| Lewis Sara Grootwassink | Director | 2026-05-06 | Grant/award | 9744 | $0 |
| Lias-Booker Ava | Director | 2026-05-06 | Grant/award | 9744 | $0 |
| Sandstrom Katherine M | Director | 2026-05-06 | Grant/award | 9744 | $0 |
| Weiss Richard A. | Director | 2026-05-06 | Grant/award | 9744 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
The risk profile has deteriorated materially across five or more distinct themes, driven by the pending Janus Living REIT offering — which introduces execution risk, governance conflicts, share-price exposure, and management distraction — compounded by a $1.1B (12.6%) debt increase, new macro headwinds (NIH cuts, tariffs, Medicaid/ACA changes, recession risk), and escalating regulatory and litigation exposures. The Janus Living transaction alone represents a structural strategic shift with cascading governance, capital, and operational consequences. A single easing (removal of a client-concentration risk) is insufficient to offset the breadth and severity of new worsening disclosures.
9 company-specific · 1 eased/removed · 3 common-mode
New disclosure of material policy risks: NIH funding cuts, visa restrictions, tariffs, Medicaid/ACA changes directly threaten tenant viability and rent payments.
Risks Related to Our Business and Operations Changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration could adversely affect our business…
New disclosure of pending Janus Living REIT offering with material execution, market, and management distraction risks. Substantial capital structure and strategic change.
Risks Related to the Pending Janus Living Offering and Our Relationship with Janus Living if the Janus Living Offering is Completed The pending Janus Living Offering may not be completed on the…
New material risk from Janus Living offering: significant economic exposure to stock price volatility, loss of control if management role ends, and inability to dispose of shares favorably.
We will have significant economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living may be limited. Following the Janus…
Merger integration risks removed; new material risks from pending Janus Living Offering and relationship disclosed, indicating significant strategic transaction.
ITEM 1A. Risk Factors The section below discusses the risk factors that may materially adversely affect our business, results of operations, and financial condition. Additional risks not presently…
New disclosure of AI/automation risk reducing tenant space demand; added NIH funding cut risk; clarified funding unavailability threat to rent payments.
Our lab tenants face significant regulation, funding requirements, and uncertainty. Our lab tenants face substantial requirements for, and risks related to, the research, development, clinical…
New disclosure of legislative risk to REIT ownership of healthcare properties, including potential restrictions and tax benefit reductions. Substantive regulatory threat.
We depend on real estate investments, particularly in the healthcare property sector, making us more vulnerable to events affecting the healthcare property sector, including a downturn or slowdown in…
New disclosure of material risk: AI adoption by tenants may reduce space demand, requiring material mitigation efforts or causing adverse financial impact.
The use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors presents risks and challenges that may adversely impact our business and operating results…
Outstanding debt increased from $8.7B to $9.8B—a $1.1B (12.6%) increase. Material deterioration in leverage position warranting investor attention.
Our level of indebtedness may increase and materially adversely affect our future operations. Our outstanding indebtedness as of December 31, 2025 was approximately $9.8 billion. We may incur…
New disclosure of material conflicts of interest between company and Janus Living involving overlapping officers/directors, dual fiduciary duties, and potential adverse tax consequences from asset dispositions.
There are conflicts of interest in our relationship with Janus Living and our officers and/or directors who are also officers and/or directors of Janus Living. We may be subject to conflicts of…
Removal of material client relationship risk suggests either improved competitive position, reduced customer concentration, or changed business model. Material positive change.
We may be unable to develop, maintain, or expand hospital and health system client relationships. We invest significant time in developing, maintaining, and expanding relationships with both new and…
New risk added: changes to regulatory, funding, staffing, trade policies by U.S. political administration. Reflects heightened political/regulatory uncertainty.
Risk Factors Summary Investors should consider the risks and uncertainties described below that may affect our business and future financial performance. These and other risks and uncertainties are…
Added explicit language that outsized jury verdicts could exceed insurance limits or lack coverage entirely, materially escalating uninsured litigation risk exposure.
We may be affected by unfavorable resolution of litigation or disputes and rising liability and insurance costs as a result thereof or other market factors. Our tenants, operators, property managers…
Added explicit recession risk, inability to pass costs to tenants, and extended elevated rate scenarios. Escalates macroeconomic impact beyond prior year's interest rate discussion.
Increased interest rates and borrowing costs could materially adversely impact our business and ability to refinance existing debt, sell properties, and conduct investment activities. U.S. government…
Healthpeak Properties issued a press release on August 4, 2026 disclosing second quarter 2026 financial results, including net income of $0.08 per share, FFO as Adjusted of $0.46 per share, and updated full-year 2026 earnings guidance with a $0.02 increase to the midpoint. The disclosure was furnished via press release (Exhibit 99.1) and supplemental report (Exhibit 99.2).
View raw filing on EDGAR →